Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...
Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.
H. Lundbeck A/S (Lundbeck) announces that, after 12 years of dedicated service on Lundbeck’s Board of Directors, Lars Søren Rasmussen has informed his decision not to seek re-election at the Annual ...
Alcohol-related deaths increased 18% during the pandemic, as did hospitalizations related to alcohol use, according to new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj ...
Albany Medical College; Director, Comprehensive Pain Center and Pain Management Fellowship, Albany Medical Center, Albany, New York Charles E. Argoff, MD, has disclosed the following relevant ...
As one of the world’s foremost medical universities, KI accounts for the single largest share of all academic medical research conducted in Sweden. KI also offers the country’s broadest range of ...
As with all observational studies, our results could be biased by unrecognised confounders and may not be generalisable to other populations of women, men, or those with other medical conditions. It ...